GB0607798D0 - Novel polypeptides and use thereof - Google Patents

Novel polypeptides and use thereof

Info

Publication number
GB0607798D0
GB0607798D0 GBGB0607798.6A GB0607798A GB0607798D0 GB 0607798 D0 GB0607798 D0 GB 0607798D0 GB 0607798 A GB0607798 A GB 0607798A GB 0607798 D0 GB0607798 D0 GB 0607798D0
Authority
GB
United Kingdom
Prior art keywords
novel polypeptides
polypeptides
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0607798.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alligator Bioscience AB
Original Assignee
Alligator Bioscience AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alligator Bioscience AB filed Critical Alligator Bioscience AB
Priority to GBGB0607798.6A priority Critical patent/GB0607798D0/en
Publication of GB0607798D0 publication Critical patent/GB0607798D0/en
Priority to JP2009505959A priority patent/JP2009534026A/en
Priority to AU2007242584A priority patent/AU2007242584A1/en
Priority to EP07732483A priority patent/EP2007797A2/en
Priority to CNA2007800231837A priority patent/CN101472942A/en
Priority to CA002649589A priority patent/CA2649589A1/en
Priority to US12/297,860 priority patent/US8173774B2/en
Priority to PCT/GB2007/001443 priority patent/WO2007122400A2/en
Priority to JP2013149291A priority patent/JP2014001212A/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
GBGB0607798.6A 2006-04-20 2006-04-20 Novel polypeptides and use thereof Ceased GB0607798D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB0607798.6A GB0607798D0 (en) 2006-04-20 2006-04-20 Novel polypeptides and use thereof
JP2009505959A JP2009534026A (en) 2006-04-20 2007-04-20 Novel polypeptides and uses thereof
AU2007242584A AU2007242584A1 (en) 2006-04-20 2007-04-20 Novel polypeptides and use thereof
EP07732483A EP2007797A2 (en) 2006-04-20 2007-04-20 Variants of the chemotaxis inhibitory protein of staphylococcus aureus
CNA2007800231837A CN101472942A (en) 2006-04-20 2007-04-20 Novel polypeptides and use thereof
CA002649589A CA2649589A1 (en) 2006-04-20 2007-04-20 Novel polypeptides and use thereof
US12/297,860 US8173774B2 (en) 2006-04-20 2007-04-20 Polypeptides and use thereof
PCT/GB2007/001443 WO2007122400A2 (en) 2006-04-20 2007-04-20 Novel polypeptides and use thereof
JP2013149291A JP2014001212A (en) 2006-04-20 2013-07-18 Novel polypeptides and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0607798.6A GB0607798D0 (en) 2006-04-20 2006-04-20 Novel polypeptides and use thereof

Publications (1)

Publication Number Publication Date
GB0607798D0 true GB0607798D0 (en) 2006-05-31

Family

ID=36580920

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0607798.6A Ceased GB0607798D0 (en) 2006-04-20 2006-04-20 Novel polypeptides and use thereof

Country Status (8)

Country Link
US (1) US8173774B2 (en)
EP (1) EP2007797A2 (en)
JP (2) JP2009534026A (en)
CN (1) CN101472942A (en)
AU (1) AU2007242584A1 (en)
CA (1) CA2649589A1 (en)
GB (1) GB0607798D0 (en)
WO (1) WO2007122400A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0607798D0 (en) * 2006-04-20 2006-05-31 Alligator Bioscience Ab Novel polypeptides and use thereof
EP2032597A2 (en) * 2006-06-16 2009-03-11 UMC Utrecht Holding B.V. Fplr-1 inhibitors for use in diseases involving amyloid-induced inflammatory events (flipr and flipr-like) and immunecomplex-mediated diseases
GB0905790D0 (en) 2009-04-03 2009-05-20 Alligator Bioscience Ab Novel polypeptides and use thereof
WO2011012316A2 (en) * 2009-07-31 2011-02-03 Ludwig-Maximilians-Universität Rna with a combination of unmodified and modified nucleotides for protein expression
KR101335203B1 (en) 2010-03-26 2013-11-29 숙명여자대학교산학협력단 Peptides for Promotion of Angiogenesis and the use thereof
CN104011072B (en) * 2011-05-05 2018-10-12 阿尔布梅迪克斯医疗有限公司 albumin variants
JP6384037B2 (en) * 2013-10-25 2018-09-05 味の素株式会社 Target material binding peptide and screening method thereof
CN107583699A (en) * 2017-09-27 2018-01-16 河南科技大学第附属医院 A kind of heparin tube examined for clinical medicine and preparation method thereof
CN113209285B (en) * 2021-04-22 2023-03-10 成都欧林生物科技股份有限公司 Application of helicobacter pylori chemotactic factor chemotaxis gene

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) * 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) * 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
LU88257I2 (en) * 1978-12-22 1994-02-03
US4530901A (en) * 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4485045A (en) * 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4678751A (en) * 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) * 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) * 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) * 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
CA2072249C (en) * 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
WO1996010585A1 (en) * 1994-09-30 1996-04-11 Inex Pharmaceuticals Corp. Glycosylated protein-liposome conjugates and methods for their preparation
US5545531A (en) * 1995-06-07 1996-08-13 Affymax Technologies N.V. Methods for making a device for concurrently processing multiple biological chip assays
GB9712512D0 (en) 1997-06-16 1997-08-20 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
AU4935999A (en) * 1998-07-10 2000-02-01 Jari Pharmaceuticals B.V Chemotaxis-inhibiting protein of (staphylococcus) (chips) and its use
EP1118663A1 (en) * 2000-01-07 2001-07-25 Universiteit Utrecht Nucleic acids encoding chemotaxis inhibitory polypeptides
PT1341909E (en) 2000-12-12 2005-10-31 Alligator Bioscience Ab METHOD FOR THE IN VITRO MOLECULAR EVOLUTION OF PROTEIN FUNCTION
GB0107661D0 (en) * 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
WO2003006048A1 (en) * 2001-07-11 2003-01-23 Jari Pharmaceuticals B.V. Combination of chips (chemotaxis inhibiting protein from staphylococcus aureus)-based compounds
US7262012B2 (en) 2002-05-17 2007-08-28 Alligator Bioscience Ab Method for in vitro molecular evolution of protein function using varied exonuclease digestion in two polynucleotide populations
AU2003257032A1 (en) * 2002-08-02 2004-02-23 Human Genome Sciences, Inc. Antibodies against c3a receptor
EP1586583A3 (en) * 2004-04-16 2005-11-16 Alligator Bioscience AB (publ) Compounds that block C5a complement receptor and their use in therapy
GB2432366B (en) 2005-11-19 2007-11-21 Alligator Bioscience Ab A method for in vitro molecular evolution of protein function
GB0607798D0 (en) 2006-04-20 2006-05-31 Alligator Bioscience Ab Novel polypeptides and use thereof
EP2032597A2 (en) * 2006-06-16 2009-03-11 UMC Utrecht Holding B.V. Fplr-1 inhibitors for use in diseases involving amyloid-induced inflammatory events (flipr and flipr-like) and immunecomplex-mediated diseases
GB0905790D0 (en) * 2009-04-03 2009-05-20 Alligator Bioscience Ab Novel polypeptides and use thereof
SG173533A1 (en) * 2009-02-06 2011-10-28 Technophage Investigacao E Desenvolvimento Em Biotecnologia Sa Antibacterial phage, phage peptides and methods of use thereof

Also Published As

Publication number Publication date
JP2009534026A (en) 2009-09-24
WO2007122400A2 (en) 2007-11-01
AU2007242584A1 (en) 2007-11-01
AU2007242584A2 (en) 2009-11-26
WO2007122400A9 (en) 2009-05-07
US8173774B2 (en) 2012-05-08
CA2649589A1 (en) 2007-11-01
CN101472942A (en) 2009-07-01
US20100298539A1 (en) 2010-11-25
EP2007797A2 (en) 2008-12-31
WO2007122400A3 (en) 2008-03-27
JP2014001212A (en) 2014-01-09

Similar Documents

Publication Publication Date Title
EP1976864A4 (en) Novel peptide and use thereof
IL218776A0 (en) Modified factor vii polypeptides and uses thereof
TWI561237B (en) Substituted dihydropyrazolones and their use
ZA200810323B (en) Fkbp-l and uses thereof
IL179300A0 (en) Novel-antigen-binding polypeptides and their uses
PL2064327T3 (en) Dbait and uses thereof
GB0708376D0 (en) Novel polypeptides and uses thereof
HK1145506A1 (en) Peptides and their use
HK1133552A1 (en) Carboranylporphyrins and uses thereof
GB0621513D0 (en) Novel polypeptides and uses thereof
HRP20150195T1 (en) Peptides and their use
GB0607798D0 (en) Novel polypeptides and use thereof
GB0702022D0 (en) Peptides and their use
IL195525A0 (en) Replikin peptides and uses thereof
GB0604187D0 (en) Peptide and uses thereof
EP2069371A4 (en) Organo-arsenoxide compounds and use thereof
EP2133326A4 (en) Novel pseudoglycolipid and use thereof
PL2046830T3 (en) Csf3r polypeptides and uses thereof
GB0623539D0 (en) Polypeptides
IL192820A0 (en) Novel compounds and use thereof
PL2032708T3 (en) Recombinant novirhabdoviruses and uses thereof
GB0516571D0 (en) Novel polypeptides and uses thereof
GB0608797D0 (en) Novel agents and the use thereof
IL192800A0 (en) Fgf2-binding peptides and uses thereof
EP1876238A4 (en) Novel polypeptide and use thereof

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)